VIVUS News

Tuesday saw what this strategist likes to affectionately call the latest serving of "takeover chowder" and what many other traders call the rumor mill.

Abbott Labs ' Meridia is supposed to make patients healthier by helping them lose weight, but it looks like it's having the opposite effect in some patients.

Nyse Arca Biotechnology Inde /marketstate/country/ 9:52:11 am 9:52:11 am 887.14 Change -9.65 -1.08% Volume 0.00 $BTK Kiosk Intraday data provided by Interactive Data Real Time Services , a division of Interactive Data Corp.

Vivus is raising the bar on erectile dysfunction drugs, potentially becoming the latest formidable competitor to Viagra and Cialis in the $3.8 billion market.

Vivus Inc ., an unprofitable biotechnology company, said its experimental impotence drug helped men in a study achieve erections in 30 minutes.

VIVUS, Inc. today announced positive results from REVIVE , a phase 3 pivotal study evaluating the safety and efficacy of avanafil, an investigational drug candidate for the treatment of erectile dysfunction , in 646 patients.

Vivus Inc. shares rose Wednesday on news that its erectile dysfunction drug was effective in a late stage trial, putting the biotech firm on course to file an application with the Food and Drug Administration in 2011.

The following stocks were among those that moved substantially or traded heavily Wednesday on the New York Stock Exchange: NYSE: Coventry Health Care Inc., down 63 cents at $23.05 An analyst said the health insurer will likely offer a disappointing 2010 earnings outlook and may be hit hard by health care reforms.

VIVUS has been plodding along over the past decade, but after a pair of successful clinical trials for its weight-loss drug, Qnexa, the company is now getting some good clinical trial data for erectile-dysfunction drug avanafil .

A drug being developed by a California company was shown in a trial to be effective in 30 minutes or less, much faster than its competitors, the maker of treatments for erectile dysfunctions said today.

Autodesk Inc. shares dropped nearly 10% Tuesday evening after the design software maker provided a soft operating-margin forecast.

A complete list of all headlines and biomedical stock developments can be found on BioMedReports.Com On 11/05/09, Isis Pharmaceuticals, Inc.

Dallas, TX - MicroStrategy Incorporated was one of the most active gainers as it rallied over 18.83% to close at $87.27 on huge volume of 1.50 million shares after the company yesterday announced financial results for the three-month period ended September 30, 2009.

Vivus Inc. on Tuesday named Peter Tam president, taking over the role from Leland Wilson.

Vivus Inc. promoted Peter Tam, its chief operating officer, to president. That title was held previously by CEO Leland Wilson, who will now be just CEO.

Investors are waiting for big obesity drug marketing deals from Vivus , Arena Pharmaceuticals and Orexigen Therapeutics , yet the first pact signed Sunday night comes from Amylin Pharmaceuticals ?!?! It's actually not that much of a surprise.

Futures were in the red Friday morning coming off Thursdaya s 200-point rally as traders work through personal income and spending numbers and wait for consumer sentiment data and Chicago PMI releases.

VIVUS announces data from Qnexa Phase III studies at The Obesity Society 27th annual scientific meeting Published in M2Europharma on Friday, 30 October 2009 at 21:38 GMT 30 October 2009 - US-based biopharmaceutical company VIVUS Inc today announced that additional data on Qnexa, an investigational drug candidate for obesity, was presented at the ...

More specifically, the biopharmaceutical firm gave an upbeat update on the late-stage study of experimental weight-loss drug Qnexa.

PicksThatMove is pleased to bring investors special situation stocks which have a high potential for price appreciation.